SCHEMBL4847800

SCHEMBL4847800

CN(C)CCOc1ccc(-c2ccccc2C(F)(F)F)cc1C(=O)C=Cc1ccccc1CN(C)C

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
ATM Q13315 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAOB P27338 1/20 0.42
SLC6A9 P48067 4/20 0.40
NFE2L2 Q16236 2/20 0.39
KEAP1 Q14145 1/20 0.39
UTS2R Q9UKP6 1/20 0.39
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HRH1 P35367 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4857391 1.00 SMN1; SMN2 (0.45) SMN1; SMN2LMNAGAAMAPTATM
SCHEMBL4847804 0.90 MAOB (0.42) SMN1; SMN2LMNAGAAMAPTATM
SCHEMBL4856330 0.89 ALDH1A1 (0.41) SMN1; SMN2LMNAGAAMAPTATM
SCHEMBL4854758 0.89 ALDH1A1 (0.41) SMN1; SMN2LMNAGAAMAPTATM
SCHEMBL4851088 0.88 ALDH1A1 (0.41) SMN1; SMN2SLC6A9KDM4EALDH1A1HRH1
SCHEMBL4852630 0.88 ALDH1A1 (0.41) SMN1; SMN2SLC6A9KDM4EALDH1A1HRH1
SCHEMBL4847435 0.88 SLC6A9 (0.46) SMN1; SMN2SLC6A9KDM4EALDH1A1HRH1
SCHEMBL4853595 0.88 AR (0.41) SMN1; SMN2MAOBSLC6A9KDM4EALDH1A1
SCHEMBL4854710 0.88 AR (0.41) SMN1; SMN2MAOBSLC6A9KDM4EALDH1A1
SCHEMBL4857272 0.88 AR (0.41) SMN1; SMN2SLC6A9UTS2RKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7423181-B2 in particular against bacterial and parasitic infections, fungi, and helminths; improved metabolic and physiochemical properties, bioavailability, solubility; 3-[4-(2-Dimethylamino-ethoxy)-2'-trifluoromethyl-biphenyl-3-yl]-1-(2-dimethylaminomethyl-phenyl)-propenone LICA PHARMACEUTICALS A/S (DK) 2008-09-09 US claimed
US-20050227990-A1 Aminoalkoxy-functional chalcones LICA PHARMACEUTICALS A/S (DK) 2005-10-13 US claimed
EP-1515940-A2 AMINOALKOXY-FUNCTIONAL CHALCONES Lica Pharmaceuticals A/S (DK) 2005-03-23 EP claimed
WO-2003097574-A2 AMINOALKOXY-FUNCTIONAL CHALCONES LICA PHARMACEUTICALS A/S (DK) 2003-11-27 WO claimed
US-7423181-B2 in particular against bacterial and parasitic infections, fungi, and helminths; improved metabolic and physiochemical properties, bioavailability, solubility; 3-[4-(2-Dimethylamino-ethoxy)-2'-trifluoromethyl-biphenyl-3-yl]-1-(2-dimethylaminomethyl-phenyl)-propenone LICA PHARMACEUTICALS A/S (DK) 2008-09-09 US disclosed
US-20050227990-A1 Aminoalkoxy-functional chalcones LICA PHARMACEUTICALS A/S (DK) 2005-10-13 US disclosed
EP-1515940-A2 AMINOALKOXY-FUNCTIONAL CHALCONES Lica Pharmaceuticals A/S (DK) 2005-03-23 EP disclosed
WO-2003097574-A2 AMINOALKOXY-FUNCTIONAL CHALCONES LICA PHARMACEUTICALS A/S (DK) 2003-11-27 WO disclosed